Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
Annals of Hematology
|
October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
Blood Cancer Journal
|
May 20, 2020
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
Roberto Mina, Angelo Belotti, Maria Teresa Petrucci, et al.
The Lancet. Haematology
|
August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Haematologica
|
May 2, 2020
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
Antonio G Solimando, Matteo C Da Vià, Patrizia Leone, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
Annals of Hematology
|
October 25, 2018
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)
Pellegrino Musto, Vittorio Simeon, Nicola Cascavilla, et al.
Blood Cancer Journal
|
May 20, 2020
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
Roberto Mina, Angelo Belotti, Maria Teresa Petrucci, et al.
The Lancet. Haematology
|
August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial
Sara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.
Journal of Hematology & Oncology
|
January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Journal of Cancer Research and Clinical Oncology
|
April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
Chiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
Antonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica
|
March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival
Antonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Haematologica
|
August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
Sara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.
Haematologica
|
May 2, 2020
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
Antonio G Solimando, Matteo C Da Vià, Patrizia Leone, et al.
Page
of 14